A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Last updated: April 4, 2025
Sponsor: Bristol-Myers Squibb
Overall Status: Completed

Phase

N/A

Condition

Myelofibrosis

Post-polycythemia Vera Myelofibrosis

Treatment

N/A

Clinical Study ID

NCT05665192
CA054-1014
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to determine real-world patient-reported outcomes with fedratinib (FEDR) therapy for myelofibrosis (MF) in the real-world (RW) setting.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosed with Primary myelofibrosis (PMF), post- Essential thrombocythemia (ET)Myelofibrosis (MF), or post- Polycythemia vera (PV) MF

  • Treated with FEDR and initiated treatment after 16 August 2019.

  • Received prior treatment with RUX.

  • Had spleen assessed at time of initiation of FEDR by palpation.

  • Able to read and speak English

  • Willing to provide informed consent

  • Willing to provide permission to the site to release her/his medical information tothe study investigators according to the study-specific eCRF

  • Willing to complete the baseline survey prior to first FEDR

Exclusion

Exclusion Criteria:

  • Past or current participant in any FEDR-related clinical trial

Study Design

Total Participants: 150
Study Start date:
August 02, 2021
Estimated Completion Date:
July 24, 2023

Connect with a study center

  • Local Institution

    City, State 00000
    Austria

    Site Not Available

  • Cardinal Health Specialty Solutions

    Dublin, Ohio 43017
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.